Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 34 entries
Sorted by: Best Match Show Resources per page
Parameter estimation in a Holzapfel-Ogden law for healthy myocardium.

Journal of engineering mathematics

Gao H, Li WG, Cai L, Berry C, Luo XY.
PMID: 26663931
J Eng Math. 2015;95(1):231-248. doi: 10.1007/s10665-014-9740-3. Epub 2015 Jan 30.

A central problem in biomechanical studies of personalized human left ventricular (LV) modelling is to estimate material properties from in vivo clinical measurements. In this work we evaluate the passive myocardial mechanical properties inversely from the in vivo LV...

Cite
Gao H, Li WG, Cai L, et al. Parameter estimation in a Holzapfel-Ogden law for healthy myocardium. J Eng Math. 2015;95(1):231-248doi: 10.1007/s10665-014-9740-3.
Gao, H., Li, W. G., Cai, L., Berry, C., & Luo, X. Y. (2015). Parameter estimation in a Holzapfel-Ogden law for healthy myocardium. Journal of engineering mathematics, 95(1), 231-248. https://doi.org/10.1007/s10665-014-9740-3
Gao, H, et al. "Parameter estimation in a Holzapfel-Ogden law for healthy myocardium." Journal of engineering mathematics vol. 95,1 (2015): 231-248. doi: https://doi.org/10.1007/s10665-014-9740-3
Gao H, Li WG, Cai L, Berry C, Luo XY. Parameter estimation in a Holzapfel-Ogden law for healthy myocardium. J Eng Math. 2015;95(1):231-248. doi: 10.1007/s10665-014-9740-3. Epub 2015 Jan 30. PMID: 26663931; PMCID: PMC4662962.
Copy Download .nbib Format: NLM
Corrigendum to "Metformin suppresses adipogenesis through both AMP-activated protein kinase (AMPK)-dependent and AMPK-independent mechanisms" [Mol. Cell. Endocrinol. 440 15 January 2017 57-68].

Molecular and cellular endocrinology

Chen SC, Brooks R, Houskeeper J, Bremner SK, Dunlop J, Viollet B, Logan PJ, Salt IP, Ahmed SF, Yarwood SJ.
PMID: 28183460
Mol Cell Endocrinol. 2017 Mar 05;443:176. doi: 10.1016/j.mce.2017.01.049.

No abstract available.

Cite
Chen SC, Brooks R, Houskeeper J, et al. Corrigendum to "Metformin suppresses adipogenesis through both AMP-activated protein kinase (AMPK)-dependent and AMPK-independent mechanisms" [Mol. Cell. Endocrinol. 440 15 January 2017 57-68]. Mol Cell Endocrinol. 2017;443:176doi: 10.1016/j.mce.2017.01.049.
Chen, S. C., Brooks, R., Houskeeper, J., Bremner, S. K., Dunlop, J., Viollet, B., Logan, P. J., Salt, I. P., Ahmed, S. F., & Yarwood, S. J. (2017). Corrigendum to "Metformin suppresses adipogenesis through both AMP-activated protein kinase (AMPK)-dependent and AMPK-independent mechanisms" [Mol. Cell. Endocrinol. 440 15 January 2017 57-68]. Molecular and cellular endocrinology, 443176. https://doi.org/10.1016/j.mce.2017.01.049
Chen, S C, et al. "Corrigendum to "Metformin suppresses adipogenesis through both AMP-activated protein kinase (AMPK)-dependent and AMPK-independent mechanisms" [Mol. Cell. Endocrinol. 440 15 January 2017 57-68]." Molecular and cellular endocrinology vol. 443 (2017): 176. doi: https://doi.org/10.1016/j.mce.2017.01.049
Chen SC, Brooks R, Houskeeper J, Bremner SK, Dunlop J, Viollet B, Logan PJ, Salt IP, Ahmed SF, Yarwood SJ. Corrigendum to "Metformin suppresses adipogenesis through both AMP-activated protein kinase (AMPK)-dependent and AMPK-independent mechanisms" [Mol. Cell. Endocrinol. 440 15 January 2017 57-68]. Mol Cell Endocrinol. 2017 Mar 05;443:176. doi: 10.1016/j.mce.2017.01.049. PMID: 28183460; PMCID: PMC6854454.
Copy Download .nbib Format: NLM
Growth hormone deficiency during young adulthood and the benefits of growth hormone replacement.

Endocrine connections

Ahmid M, Perry CG, Ahmed SF, Shaikh MG.
PMID: 27129699
Endocr Connect. 2016 May;5(3):R1-R11. doi: 10.1530/EC-16-0024. Epub 2016 Apr 29.

Until quite recently, the management of children with growth hormone deficiency (GHD) had focussed on the use of recombinant human GH (rhGH) therapy to normalise final adult height. However, research over the past two decades that has demonstrated deficits...

Cite
Ahmid M, Perry CG, Ahmed SF, et al. Growth hormone deficiency during young adulthood and the benefits of growth hormone replacement. Endocr Connect. 2016;5(3):R1-R11doi: 10.1530/EC-16-0024.
Ahmid, M., Perry, C. G., Ahmed, S. F., & Shaikh, M. G. (2016). Growth hormone deficiency during young adulthood and the benefits of growth hormone replacement. Endocrine connections, 5(3), R1-R11. https://doi.org/10.1530/EC-16-0024
Ahmid, M, et al. "Growth hormone deficiency during young adulthood and the benefits of growth hormone replacement." Endocrine connections vol. 5,3 (2016): R1-R11. doi: https://doi.org/10.1530/EC-16-0024
Ahmid M, Perry CG, Ahmed SF, Shaikh MG. Growth hormone deficiency during young adulthood and the benefits of growth hormone replacement. Endocr Connect. 2016 May;5(3):R1-R11. doi: 10.1530/EC-16-0024. Epub 2016 Apr 29. PMID: 27129699; PMCID: PMC5002964.
Copy Download .nbib Format: NLM
fMRI at High Spatial Resolution: Implications for BOLD-Models.

Frontiers in computational neuroscience

Goense J, Bohraus Y, Logothetis NK.
PMID: 27445782
Front Comput Neurosci. 2016 Jun 28;10:66. doi: 10.3389/fncom.2016.00066. eCollection 2016.

As high-resolution functional magnetic resonance imaging (fMRI) and fMRI of cortical layers become more widely used, the question how well high-resolution fMRI signals reflect the underlying neural processing, and how to interpret laminar fMRI data becomes more and more...

Cite
Goense J, Bohraus Y, Logothetis NK. fMRI at High Spatial Resolution: Implications for BOLD-Models. Front Comput Neurosci. 2016;10:66doi: 10.3389/fncom.2016.00066.
Goense, J., Bohraus, Y., & Logothetis, N. K. (2016). fMRI at High Spatial Resolution: Implications for BOLD-Models. Frontiers in computational neuroscience, 1066. https://doi.org/10.3389/fncom.2016.00066
Goense, Jozien, et al. "fMRI at High Spatial Resolution: Implications for BOLD-Models." Frontiers in computational neuroscience vol. 10 (2016): 66. doi: https://doi.org/10.3389/fncom.2016.00066
Goense J, Bohraus Y, Logothetis NK. fMRI at High Spatial Resolution: Implications for BOLD-Models. Front Comput Neurosci. 2016 Jun 28;10:66. doi: 10.3389/fncom.2016.00066. eCollection 2016. PMID: 27445782; PMCID: PMC4923185.
Copy Download .nbib Format: NLM
Abnormal Connectional Fingerprint in Schizophrenia: A Novel Network Analysis of Diffusion Tensor Imaging Data.

Frontiers in psychiatry

Edwin Thanarajah S, Han CE, Rotarska-Jagiela A, Singer W, Deichmann R, Maurer K, Kaiser M, Uhlhaas PJ.
PMID: 27445870
Front Psychiatry. 2016 Jun 30;7:114. doi: 10.3389/fpsyt.2016.00114. eCollection 2016.

The graph theoretical analysis of structural magnetic resonance imaging (MRI) data has received a great deal of interest in recent years to characterize the organizational principles of brain networks and their alterations in psychiatric disorders, such as schizophrenia. However,...

Cite
Edwin Thanarajah S, Han CE, Rotarska-Jagiela A, et al. Abnormal Connectional Fingerprint in Schizophrenia: A Novel Network Analysis of Diffusion Tensor Imaging Data. Front Psychiatry. 2016;7:114doi: 10.3389/fpsyt.2016.00114.
Edwin Thanarajah, S., Han, C. E., Rotarska-Jagiela, A., Singer, W., Deichmann, R., Maurer, K., Kaiser, M., & Uhlhaas, P. J. (2016). Abnormal Connectional Fingerprint in Schizophrenia: A Novel Network Analysis of Diffusion Tensor Imaging Data. Frontiers in psychiatry, 7114. https://doi.org/10.3389/fpsyt.2016.00114
Edwin Thanarajah, Sharmili, et al. "Abnormal Connectional Fingerprint in Schizophrenia: A Novel Network Analysis of Diffusion Tensor Imaging Data." Frontiers in psychiatry vol. 7 (2016): 114. doi: https://doi.org/10.3389/fpsyt.2016.00114
Edwin Thanarajah S, Han CE, Rotarska-Jagiela A, Singer W, Deichmann R, Maurer K, Kaiser M, Uhlhaas PJ. Abnormal Connectional Fingerprint in Schizophrenia: A Novel Network Analysis of Diffusion Tensor Imaging Data. Front Psychiatry. 2016 Jun 30;7:114. doi: 10.3389/fpsyt.2016.00114. eCollection 2016. PMID: 27445870; PMCID: PMC4928135.
Copy Download .nbib Format: NLM
Rivaroxaban for secondary stroke prevention in patients with embolic strokes of undetermined source: Design of the NAVIGATE ESUS randomized trial.

European stroke journal

Hart RG, Sharma M, Mundl H, Shoamanesh A, Kasner SE, Berkowitz SD, Pare G, Kirsch B, Pogue J, Pater C, Peters G, Davalos A, Lang W, Wang Y, Wang Y, Cunha L, Eckstein J, Tatlisumak T, Shamalov N, Mikulik R, Lavados P, Hankey GJ, Czlonkowska A, Toni D, Ameriso SF, Gagliardi RJ, Amarenco P, Bereczki D, Uchiyama S, Lindgren A, Endres M, Brouns R, Yoon BW, Ntaios G, Veltkamp R, Muir KW, Ozturk S, Arauz A, Bornstein N, Bryer A, O'Donnell MJ, Weitz J, Peacock F, Themeles E, Connolly SJ.
PMID: 31008276
Eur Stroke J. 2016 Sep;1(3):146-154. doi: 10.1177/2396987316663049. Epub 2016 Aug 03.

BACKGROUND: Embolic strokes of undetermined source comprise up to 20% of ischemic strokes. The stroke recurrence rate is substantial with aspirin, widely used for secondary prevention. The New Approach riVaroxaban Inhibition of Factor Xa in a Global trial versus...

Cite
Hart RG, Sharma M, Mundl H, et al. Rivaroxaban for secondary stroke prevention in patients with embolic strokes of undetermined source: Design of the NAVIGATE ESUS randomized trial. Eur Stroke J. 2016;1(3):146-154doi: 10.1177/2396987316663049.
Hart, R. G., Sharma, M., Mundl, H., Shoamanesh, A., Kasner, S. E., Berkowitz, S. D., Pare, G., Kirsch, B., Pogue, J., Pater, C., Peters, G., Davalos, A., Lang, W., Wang, Y., Wang, Y., Cunha, L., Eckstein, J., Tatlisumak, T., Shamalov, N., Mikulik, R., Lavados, P., Hankey, G. J., Czlonkowska, A., Toni, D., Ameriso, S. F., Gagliardi, R. J., Amarenco, P., Bereczki, D., Uchiyama, S., Lindgren, A., Endres, M., Brouns, R., Yoon, B. W., Ntaios, G., Veltkamp, R., Muir, K. W., Ozturk, S., Arauz, A., Bornstein, N., Bryer, A., O'Donnell, M. J., Weitz, J., Peacock, F., Themeles, E., & Connolly, S. J. (2016). Rivaroxaban for secondary stroke prevention in patients with embolic strokes of undetermined source: Design of the NAVIGATE ESUS randomized trial. European stroke journal, 1(3), 146-154. https://doi.org/10.1177/2396987316663049
Hart, Robert G, et al. "Rivaroxaban for secondary stroke prevention in patients with embolic strokes of undetermined source: Design of the NAVIGATE ESUS randomized trial." European stroke journal vol. 1,3 (2016): 146-154. doi: https://doi.org/10.1177/2396987316663049
Hart RG, Sharma M, Mundl H, Shoamanesh A, Kasner SE, Berkowitz SD, Pare G, Kirsch B, Pogue J, Pater C, Peters G, Davalos A, Lang W, Wang Y, Wang Y, Cunha L, Eckstein J, Tatlisumak T, Shamalov N, Mikulik R, Lavados P, Hankey GJ, Czlonkowska A, Toni D, Ameriso SF, Gagliardi RJ, Amarenco P, Bereczki D, Uchiyama S, Lindgren A, Endres M, Brouns R, Yoon BW, Ntaios G, Veltkamp R, Muir KW, Ozturk S, Arauz A, Bornstein N, Bryer A, O'Donnell MJ, Weitz J, Peacock F, Themeles E, Connolly SJ. Rivaroxaban for secondary stroke prevention in patients with embolic strokes of undetermined source: Design of the NAVIGATE ESUS randomized trial. Eur Stroke J. 2016 Sep;1(3):146-154. doi: 10.1177/2396987316663049. Epub 2016 Aug 03. PMID: 31008276; PMCID: PMC6301240.
Copy Download .nbib Format: NLM
Hypertension: Update 2020.

Hypertension (Dallas, Tex. : 1979)

Dominiczak AF, Meyer TJ.
PMID: 31786975
Hypertension. 2020 Jan;75(1):3-4. doi: 10.1161/HYPERTENSIONAHA.119.14352. Epub 2019 Dec 02.

No abstract available.

Cite
Dominiczak AF, Meyer TJ. Hypertension: Update 2020. Hypertension. 2019;75(1):3-4doi: 10.1161/HYPERTENSIONAHA.119.14352.
Dominiczak, A. F., & Meyer, T. J. (2020). Hypertension: Update 2020. Hypertension (Dallas, Tex. : 1979), 75(1), 3-4. https://doi.org/10.1161/HYPERTENSIONAHA.119.14352
Dominiczak, Anna F, and Meyer, Trudie J. "Hypertension: Update 2020." Hypertension (Dallas, Tex. : 1979) vol. 75,1 (2020): 3-4. doi: https://doi.org/10.1161/HYPERTENSIONAHA.119.14352
Dominiczak AF, Meyer TJ. Hypertension: Update 2020. Hypertension. 2020 Jan;75(1):3-4. doi: 10.1161/HYPERTENSIONAHA.119.14352. Epub 2019 Dec 02. PMID: 31786975.
Copy Download .nbib Format: NLM
Risk assessment in patients with an acute ST-elevation myocardial infarction.

Journal of comparative effectiveness research

Ahmed N, Carberry J, Teng V, Carrick D, Berry C.
PMID: 27580675
J Comp Eff Res. 2016 Nov;5(6):581-593. doi: 10.2217/cer-2016-0017. Epub 2016 Sep 01.

ST-elevation myocardial infarction (STEMI) is one of the leading causes of mortality and morbidity worldwide. While the survival after acute STEMI has considerably improved, mortality rate still remains high, especially in high-risk patients. Survival after acute STEMI is influenced...

Cite
Ahmed N, Carberry J, Teng V, et al. Risk assessment in patients with an acute ST-elevation myocardial infarction. J Comp Eff Res. 2016;5(6):581-593doi: 10.2217/cer-2016-0017.
Ahmed, N., Carberry, J., Teng, V., Carrick, D., & Berry, C. (2016). Risk assessment in patients with an acute ST-elevation myocardial infarction. Journal of comparative effectiveness research, 5(6), 581-593. https://doi.org/10.2217/cer-2016-0017
Ahmed, Nadeem, et al. "Risk assessment in patients with an acute ST-elevation myocardial infarction." Journal of comparative effectiveness research vol. 5,6 (2016): 581-593. doi: https://doi.org/10.2217/cer-2016-0017
Ahmed N, Carberry J, Teng V, Carrick D, Berry C. Risk assessment in patients with an acute ST-elevation myocardial infarction. J Comp Eff Res. 2016 Nov;5(6):581-593. doi: 10.2217/cer-2016-0017. Epub 2016 Sep 01. PMID: 27580675; PMCID: PMC5985500.
Copy Download .nbib Format: NLM
Intravenous thrombolysis for acute stroke: current standards and future directions.

Current treatment options in cardiovascular medicine

Ramani L, Huang X, Cheripelli B, Muir KW.
PMID: 25778425
Curr Treat Options Cardiovasc Med. 2015 Apr;17(4):373. doi: 10.1007/s11936-015-0373-2.

OPINION STATEMENT: Intravenous thrombolysis with the recombinant tissue plasminogen activator alteplase is the standard of care for patients with acute ischaemic stroke presenting within 4.5 h of symptom onset. The odds of independent survival decline steeply with longer time...

Cite
Ramani L, Huang X, Cheripelli B, et al. Intravenous thrombolysis for acute stroke: current standards and future directions. Curr Treat Options Cardiovasc Med. 2015;17(4):373doi: 10.1007/s11936-015-0373-2.
Ramani, L., Huang, X., Cheripelli, B., & Muir, K. W. (2015). Intravenous thrombolysis for acute stroke: current standards and future directions. Current treatment options in cardiovascular medicine, 17(4), 373. https://doi.org/10.1007/s11936-015-0373-2
Ramani, Lucille, et al. "Intravenous thrombolysis for acute stroke: current standards and future directions." Current treatment options in cardiovascular medicine vol. 17,4 (2015): 373. doi: https://doi.org/10.1007/s11936-015-0373-2
Ramani L, Huang X, Cheripelli B, Muir KW. Intravenous thrombolysis for acute stroke: current standards and future directions. Curr Treat Options Cardiovasc Med. 2015 Apr;17(4):373. doi: 10.1007/s11936-015-0373-2. PMID: 25778425.
Copy Download .nbib Format: NLM
European recommendations on organisation of interventional care in acute stroke (EROICAS).

European stroke journal

Fiehler J, Cognard C, Gallitelli M, Jansen O, Kobayashi A, Mattle HP, Muir KW, Mazighi M, Schaller K, Schellinger PD.
PMID: 31008277
Eur Stroke J. 2016 Sep;1(3):155-170. doi: 10.1177/2396987316659033. Epub 2016 Jul 26.

No abstract available.

Cite
Fiehler J, Cognard C, Gallitelli M, et al. European recommendations on organisation of interventional care in acute stroke (EROICAS). Eur Stroke J. 2016;1(3):155-170doi: 10.1177/2396987316659033.
Fiehler, J., Cognard, C., Gallitelli, M., Jansen, O., Kobayashi, A., Mattle, H. P., Muir, K. W., Mazighi, M., Schaller, K., & Schellinger, P. D. (2016). European recommendations on organisation of interventional care in acute stroke (EROICAS). European stroke journal, 1(3), 155-170. https://doi.org/10.1177/2396987316659033
Fiehler, Jens, et al. "European recommendations on organisation of interventional care in acute stroke (EROICAS)." European stroke journal vol. 1,3 (2016): 155-170. doi: https://doi.org/10.1177/2396987316659033
Fiehler J, Cognard C, Gallitelli M, Jansen O, Kobayashi A, Mattle HP, Muir KW, Mazighi M, Schaller K, Schellinger PD. European recommendations on organisation of interventional care in acute stroke (EROICAS). Eur Stroke J. 2016 Sep;1(3):155-170. doi: 10.1177/2396987316659033. Epub 2016 Jul 26. PMID: 31008277; PMCID: PMC6301238.
Copy Download .nbib Format: NLM
How many stroke patients might be eligible for mechanical thrombectomy?.

European stroke journal

Tawil SE, Cheripelli B, Huang X, Moreton F, Kalladka D, MacDougal NJ, McVerry F, Muir KW.
PMID: 31008287
Eur Stroke J. 2016 Dec;1(4):264-271. doi: 10.1177/2396987316667176. Epub 2016 Aug 30.

INTRODUCTION: Recent studies showed improved patient outcomes with endovascular treatment of acute stroke compared to medical care, including IV rtPA, alone. Seven trials have reported results, each using different clinical and imaging criteria for patient selection. We compared eligibility...

Cite
Tawil SE, Cheripelli B, Huang X, et al. How many stroke patients might be eligible for mechanical thrombectomy?. Eur Stroke J. 2016;1(4):264-271doi: 10.1177/2396987316667176.
Tawil, S. E., Cheripelli, B., Huang, X., Moreton, F., Kalladka, D., MacDougal, N. J., McVerry, F., & Muir, K. W. (2016). How many stroke patients might be eligible for mechanical thrombectomy?. European stroke journal, 1(4), 264-271. https://doi.org/10.1177/2396987316667176
Tawil, Salwa El, et al. "How many stroke patients might be eligible for mechanical thrombectomy?." European stroke journal vol. 1,4 (2016): 264-271. doi: https://doi.org/10.1177/2396987316667176
Tawil SE, Cheripelli B, Huang X, Moreton F, Kalladka D, MacDougal NJ, McVerry F, Muir KW. How many stroke patients might be eligible for mechanical thrombectomy?. Eur Stroke J. 2016 Dec;1(4):264-271. doi: 10.1177/2396987316667176. Epub 2016 Aug 30. PMID: 31008287; PMCID: PMC6301245.
Copy Download .nbib Format: NLM
Xanthine oxidase inhibition for the improvement of long-term outcomes following ischaemic stroke and transient ischaemic attack (XILO-FIST) - Protocol for a randomised double blind placebo-controlled clinical trial.

European stroke journal

Dawson J, Broomfield N, Dani K, Dickie DA, Doney A, Forbes K, Houston G, Kean S, Lees K, McConnachie A, Muir KW, Quinn T, Struthers A, Walters M.
PMID: 30246149
Eur Stroke J. 2018 Sep;3(3):281-290. doi: 10.1177/2396987318771426. Epub 2018 Apr 18.

BACKGROUND: Allopurinol, a xanthine oxidase inhibitor, reduced progression of carotid-intima media thickness and lowered blood pressure in a small clinical trial in people with ischaemic stroke. Xanthine oxidase inhibition for improvement of long-term outcomes following ischaemic stroke and transient...

Cite
Dawson J, Broomfield N, Dani K, et al. Xanthine oxidase inhibition for the improvement of long-term outcomes following ischaemic stroke and transient ischaemic attack (XILO-FIST) - Protocol for a randomised double blind placebo-controlled clinical trial. Eur Stroke J. 2018;3(3):281-290doi: 10.1177/2396987318771426.
Dawson, J., Broomfield, N., Dani, K., Dickie, D. A., Doney, A., Forbes, K., Houston, G., Kean, S., Lees, K., McConnachie, A., Muir, K. W., Quinn, T., Struthers, A., & Walters, M. (2018). Xanthine oxidase inhibition for the improvement of long-term outcomes following ischaemic stroke and transient ischaemic attack (XILO-FIST) - Protocol for a randomised double blind placebo-controlled clinical trial. European stroke journal, 3(3), 281-290. https://doi.org/10.1177/2396987318771426
Dawson, Jesse, et al. "Xanthine oxidase inhibition for the improvement of long-term outcomes following ischaemic stroke and transient ischaemic attack (XILO-FIST) - Protocol for a randomised double blind placebo-controlled clinical trial." European stroke journal vol. 3,3 (2018): 281-290. doi: https://doi.org/10.1177/2396987318771426
Dawson J, Broomfield N, Dani K, Dickie DA, Doney A, Forbes K, Houston G, Kean S, Lees K, McConnachie A, Muir KW, Quinn T, Struthers A, Walters M. Xanthine oxidase inhibition for the improvement of long-term outcomes following ischaemic stroke and transient ischaemic attack (XILO-FIST) - Protocol for a randomised double blind placebo-controlled clinical trial. Eur Stroke J. 2018 Sep;3(3):281-290. doi: 10.1177/2396987318771426. Epub 2018 Apr 18. PMID: 30246149; PMCID: PMC6120121.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 34 entries